UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported ~~September~~October 303, 2019.

NOBILIS HEALTH CORP.

(Exact name of registrant as specified in its charter)



British Columbia	001-37349	98-1188172
(State or other jurisdiction of	(Commission File	(IRS Employer Identification No.)
incorporation)	Number)



11700 Katy Freeway, Suite 300, Houston, Texas	77079
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (281) 925-0950

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Shares, no par value	Securities registered pursuant to Section 12(b) of the Act:	None

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~September~~October 303, 2019, ~~Steven~~Daniel ~~Ozonian,~~Wiggins notified the Board of Directors of Nobilis Health Corp. (the “Company”) of his ~~intention~~resignation ~~to resign~~ as ~~a director of~~ the ~~Company,~~Chief ~~effective~~Restructuring ~~September~~Officer ~~30, 2019. Mr. Ozonian’s resignation was not the result~~ of ~~any~~(i) ~~dispute or disagreement with~~ the Company, or(ii) ~~the~~a ~~Company’s~~direct ~~Board~~subsidiary, ofNorthstar ~~Directors~~Healthcare onHoldings, ~~any~~Inc., ~~matter~~and ~~relating~~(iii) toan ~~the~~indirect ~~operations~~subsidiary, ~~policies~~Northstar orHealthcare ~~practices~~Acquisitions, ofL.L.C., ~~the~~effective ~~Company~~immediately.

Item 7.01 Regulation FD Disclosure

On October 8, 2019, Daniel Wiggins notified the employees of the Company of his resignation as the Chief Restructuring Officer of the Company.

The information in this Item 7.01 of this Current Report on Form 8-K is furnished pursuant to the rules and regulations of the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOBILIS HEALTH CORP. /s/ Harry Fleming Harry Fleming Chairman Date: October 79, 2019

Filing Compare · Nobilis Health Corp.